Literature DB >> 7479711

Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine.

U Schulze-Gahmen1, J Brandsen, H D Jones, D O Morgan, L Meijer, J Vesely, S H Kim.   

Abstract

Cyclin-dependent kinases (CDKs) are conserved regulators of the eukaryotic cell cycle with different isoforms controlling specific phases of the cell cycle. Mitogenic or growth inhibitory signals are mediated, respectively, by activation or inhibition of CDKs which phosphorylate proteins associated with the cell cycle. The central role of CDKs in cell cycle regulation makes them a potential new target for inhibitory molecules with anti-proliferative and/or anti-neoplastic effects. We describe the crystal structures of the complexes of CDK2 with a weakly specific CDK inhibitor, N6-(delta 2-isopentenyl)adenine, and a strongly specific inhibitor, olomoucine. Both inhibitors are adenine derivatives and bind in the adenine binding pocket of CDK2, but in an unexpected and different orientation from the adenine of the authentic ligand ATP. The N6-benzyl substituent in olomoucine binds outside the conserved binding pocket and is most likely responsible for its specificity. The structural information from the CDK2-olomoucine complex will be useful in directing the search for the next generation inhibitors with improved properties.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7479711     DOI: 10.1002/prot.340220408

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  30 in total

1.  Chemical force microscopy with active enzymes.

Authors:  M Fiorini; R McKendry; M A Cooper; T Rayment; C Abell
Journal:  Biophys J       Date:  2001-05       Impact factor: 4.033

2.  Hot spot analysis for driving the development of hits into leads in fragment-based drug discovery.

Authors:  David R Hall; Chi Ho Ngan; Brandon S Zerbe; Dima Kozakov; Sandor Vajda
Journal:  J Chem Inf Model       Date:  2011-12-15       Impact factor: 4.956

Review 3.  The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer.

Authors:  Katrien Vermeulen; Dirk R Van Bockstaele; Zwi N Berneman
Journal:  Cell Prolif       Date:  2003-06       Impact factor: 6.831

4.  Structural basis for selectivity of the isoquinoline sulfonamide family of protein kinase inhibitors.

Authors:  R M Xu; G Carmel; J Kuret; X Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

5.  Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism.

Authors:  Alexandr P Kornev; Nina M Haste; Susan S Taylor; Lynn F Ten Eyck
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-09       Impact factor: 11.205

6.  The effect of a tightly bound water molecule on scaffold diversity in the computer-aided de novo ligand design of CDK2 inhibitors.

Authors:  Alfonso T García-Sosa; Ricardo L Mancera
Journal:  J Mol Model       Date:  2005-12-23       Impact factor: 1.810

Review 7.  Selectivity and potency of cyclin-dependent kinase inhibitors.

Authors:  Jayalakshmi Sridhar; Nagaraju Akula; Nagarajan Pattabiraman
Journal:  AAPS J       Date:  2006-03-24       Impact factor: 4.009

8.  Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modeling and biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitors.

Authors:  Karen A Rossi; Jay A Markwalder; Steven P Seitz; Chong-Hwan Chang; Sarah Cox; Michael D Boisclair; Leonardo Brizuela; Stephen L Brenner; Pieter F W Stouten
Journal:  J Comput Aided Mol Des       Date:  2005-02       Impact factor: 3.686

9.  The CRK1 receptor-like kinase gene of tobacco is negatively regulated by cytokinin.

Authors:  Silke Schäfer; Thomas Schmülling
Journal:  Plant Mol Biol       Date:  2002-09       Impact factor: 4.076

10.  Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription.

Authors:  L M Schang; J Phillips; P A Schaffer
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.